<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical trials of vaccine candidates provide important opportunities to profile the quality of antibodies generated by these vaccines. Additionally, utilizing adjuvants offers an opportunity to generate many distinct antibody responses, resulting in the potential of rationally choosing adjuvants to more specifically stimulate the types of antibody responses that may be optimal in contributing to the control of TB. Accordingly, it will be critical to continue the clinical assessment of TB candidates and to build into these trials the opportunity to assess antibody responses as well as CMI.</p>
